These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 11888075

  • 41. Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia.
    Thiele J, Kvasnicka HM, Schmitt-Graeff A, Kriener S, Engels K, Staib P, Griesshammer M, Waller CF, Ottmann OG, Hansmann ML.
    Histol Histopathol; 2004 Oct; 19(4):1277-88. PubMed ID: 15375771
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
    Thiele J, Kvasnicka HM, Beelen DW, Flucke U, Spoer C, Paperno S, Leder LD, Schaefer UW.
    Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate.
    Bocchia M, Ippoliti M, Gozzetti A, Abruzzese E, Calabrese S, Amabile M, Pirrotta MT, Crupi R, Tozzuoli D, Trawinska MM, Defina M, Martinelli G, Lauria F.
    Leukemia; 2008 Feb; 22(2):426-8. PubMed ID: 17690698
    [No Abstract] [Full Text] [Related]

  • 48. Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
    Thiele J, Kvasnicka HM, Schmitt-Graeff A, Cvetanovska G, Blum N, Schaefer HE.
    Mod Pathol; 2000 Aug; 13(8):888-96. PubMed ID: 10955456
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. [Hematological side effects of tyrosine kinase inhibition using imatinib].
    Schmitt-Graeff A, Hochhaus A.
    Pathologe; 2006 Feb; 27(1):40-6. PubMed ID: 16421705
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. [Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia].
    Kvasnicka HM, Thiele J, Staib P, Engels K, Kriener S, Schmitt-Graeff A.
    Pathologe; 2004 Mar; 25(2):127-34. PubMed ID: 15010998
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. [Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].
    Thiele J, Kvasnicka HM, Varus E, Kriener S, Engels K, Staib P, Ollig ES, Griesshammer M, Waller CF, Pfeifer H, Schmitt-Gräff A.
    Pathologe; 2004 Nov; 25(6):428-35. PubMed ID: 15179523
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.